Digital Therapeutics Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B (Providers, Payer, Employer, Pharma) - Global Forecasts to 2027
Digital Therapeutics Market Size, Global Industry Forecast
The global digital therapeutics market in terms of revenue was estimated to be worth $4.5 billion in 2022 and is poised to reach $17.7 billion by 2027, growing at a CAGR of 31.6% from 2022 to 2027. Growth in this market is primarily driven by the rising incidence of preventable chronic diseases, the need to control healthcare costs, increasing venture capital investment, and the benefits of digital therapeutics.
To know about the assumptions considered for the study, Request for Free Sample Report
Digital Therapeutics Market Dynamics
Drivers: Need to control healthcare costs
Globally, healthcare costs are on the rise owing to factors such as the rising prevalence of chronic diseases, rapid growth in the geriatric population, soaring prices of medical services, the growing demand for healthcare services, sedentary lifestyles, and the use of expensive drugs and medical technologies. In addition, operational inefficiency and rehospitalization add to rising healthcare costs.
The rising requirement to curtail growing healthcare costs is one of the key growth drivers for digital therapeutics. According to the Centers for Medicare & Medicaid Services (CMS), in 2020, national health expenditures will have grown 9.7% to USD 4.1 trillion, or USD 12,530 per person, and accounted for 19.7% of the US GDP. According to the Centers for Medicare & Medicaid Services (CMS), in 2019, US healthcare spending rose by 4.6% to USD 3.8 trillion, matching the growth rate of 4.7% in 2018. According to the World Bank, healthcare spending in Japan was 10.74 % of the GDP in 2019 and 5.35% in China. Rising healthcare costs increase the burden on the government, insurance companies, households, and national budgets.
Opportunities: Unexplored therapeutic applications
Digital therapeutics have demonstrated their ability to prevent and treat a variety of chronic diseases. Many players in this market are trying to explore innovative therapeutic areas for digital therapeutic solutions. For instance, Click Therapeutics (US) is exploring application areas such as irritable bowel syndrome, chronic pain, insomnia, and neurocognitive disorders to develop digital therapeutics. Similarly, Pear Therapeutics (US) has a pipeline of digital therapeutic solutions for unexplored disorders like schizophrenia, multiple sclerosis, epilepsy, post-traumatic stress disorder (PTSD), and traumatic brain injury. Similarly, Akili, Inc., has a product pipeline of digital therapeutic solutions for unexplored disorders like attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Unexplored therapeutic areas present immense opportunities for the growth of the digital therapeutics market.
Restraints: Patient data security concerns
In many countries, various health apps are deprived of appropriate approvals, leading to concerns about product and data quality, reliability in treatment decisions, patient privacy, security, and the accountable use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient’s data is at risk of being accessed by any healthcare professional not related to the patient’s treatment program. Some countries, such as the US (with its Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health (HITECH) Act), have legislation aimed at the issue of data security. Additionally, the European Union has the EU Data Protection Regulation, which has implications for protecting sensitive health data. In many countries, a patient’s protected health information (PHI) cannot be moved out of the country of origin. Concerns over patient health data security create barriers to transferring this data among various stakeholders in the healthcare industry. Despite such federal initiatives and laws, users of digital therapeutics are vulnerable to infringement and data breaching, which may limit the market's growth.
Challenges: Unstable payment Models
The current prevalent system of benefits and payments focuses on favourable payment models for conventional treatment options. However, they are not as compliant with alternative approaches like digital health or therapeutics. The existing system of paying for healthcare entails paying for items of care. This payment system is incapable of changing behavior. Because digital therapeutics solutions are still in the early stages of development, the exact payment mechanism for digital therapeutics is unknown. Presently, digital therapeutics are not included in formularies; getting digital therapeutics on formularies requires thorough, double-blind, and controlled clinical trials, which are complex in terms of defining a control group for these products. Additionally, the required study size for these clinical trials is also larger, which increases the total expenditure of these studies. These costs rise if digital therapeutics are partnered with a pharmaceutical company.
Furthermore, high development costs are hard to justify if the product is not supported by FDA approval and patent protection. This compels most providers to compare the cost and efficacy of their treatment against already published historical control groups. This is insufficient to convince insurers to put digital therapeutics on the formulary for all patients, making companies consider the case insurer-by-insurer to file for coverage decisions. Even without rigorous trials proving value, most companies must accept pricing models complying with the current industry norm of USD 20–200 per patient per year (source: industry expert), which is significantly lower than the average chronic drug cost of USD 200/month. This makes it imperative for digital therapeutics companies to identify better ways to support higher PMPMs. Such an unstable payment scenario poses a serious challenge to market growth.
B2B segment is expected to account for the largest share of digital therapeutics market, by Sales
The global market is divided based on sales channel into business-to-consumer (B2C) and business-to-business (B2B). This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to incorporate digital therapeutics into their drug products.
Treatment/Care related applications are the largest share of the digital therapeutics market, by applications
The global market is divided based on applications into preventive and treatment or care-related applications. The treatment and care-related applications segment is expected to hold the highest share in the market, attributed to the increasing economic burden of their treatment and investments in digital therapeutics to promote the advancement of cost-effective and scalable treatment platforms for these conditions.
North America to dominate the digital therapeutics market
The global market is divided based on regions into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the market, followed by Europe. The high growth rate of the North American market can primarily be attributed to rising enhancements in the reimbursement structure for digital therapeutics, a growing number of new start-ups in the global market investments in digital therapeutics, and government initiatives to encourage technological advancements that drive market growth in this region.
To know about the assumptions considered for the study, download the pdf brochure
Prominent players in this market includes Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US).
Digital Therapeutics Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$4.5 billion |
|
Estimated Value by 2027 |
$17.7 billion |
|
Growth Rate |
Poised to grow at a CAGR of 31.6% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
By Sales Channel, Application, And Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
Digital Therapeutics Market Report Segmentation
By Sales Channel
- B2C
- Patients
- Caregivers
- B2B
- Providers
- Payers
- Employers
- Pharmaceutical Companies
- Other Buyers
By Application
-
Preventive Applications
- Prediabetes
- Obesity
- Nutrition
- Lifestyle Management
- Other Preventive Applications
-
Treatment/Care-related Applications
- Diabetes
-
CNS Disorders
- Mental Health Disorder
- Other CNS Disorders
- Chronic Respiratory Disorders
- Musculoskeletal Disorders
- Cardiovascular Diseases
- Smoking Cessation
- Medication Adherence
- Gastrointestinal Disorders
- Substance Use & Addiction Management
- Rehabilitation & Patient Care
- Other Treatment/Care-related Applications
By Region
-
North America
- US
- Canada
-
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe (RoE)
-
APAC
- Japan
- China
- India
- Rest of the APAC
- Rest of the World (RoW)
Recent Developments:
- In August 2022, Pear Therapeutics (US) entered into an agreement with SelectHealth (US) to provide members with covered access to Pear’s innovative prescription digital therapeutic (PDT), reSET-O, for treating opioid use disorder (OUD) as an adjunct to outpatient treatment.
- In March 2022, Omada Health (US) integrated behavioral health support into its programs (Diabetes Prevention, Diabetes Management, Hypertension, and Musculoskeletal). The new behavioral health integration comprises anxiety and depression assessment, resources to manage social health determinants, like food access, stress management, and sleep tools.
- In April 2021, Welldoc (US) partnered with Dexacom (US). This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.
- In March 2021, Pear Therapeutics (US) partnered with Sprectrum Health Systems (US). Tufts Health Plan and Spectrum Health Systems announced a collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation
Frequently Asked Questions (FAQs):
What is the size of Digital Therapeutics Market?
The global digital therapeutics market crossed $4.5 billion in 2022, and is poised to grow at a CAGR of 31.6% in the next five years to reach $17.7 billion.
Why is Digital Therapeutics Market Growing?
Digital therapeutics is a rapidly growing market due to the increasing demand for cost-effective and personalized treatments for chronic diseases. Digital therapeutics are used to complement existing treatments or to replace them entirely. They offer a convenient and cost-effective way to monitor and manage chronic diseases, and to provide personalized treatment plans. Digital therapeutics also reduce the burden on healthcare systems. Additionally, the growing acceptance of digital health solutions and the increasing prevalence of chronic diseases are driving the growth of the digital therapeutics market.
Who all are the prominent players of Digital Therapeutics Market?
Prominent players in this market includes Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
FIGURE 3 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach one: Revenue mapping-based estimation
FIGURE 6 DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION
2.2.1.2 Approach two: Buyer adoption-based estimation
FIGURE 7 DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION
2.2.2 TOP-DOWN APPROACH: PaENETRATION RATE-BASED MARKET SIZE ESTIMATION
FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION
2.2.3 GROWTH FORECAST
TABLE 1 FACTOR ANALYSIS
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS
2.5 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 12 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GLOBAL MARKET FOR B2C SALES CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GLOBAL MARKET FOR B2B SALES CHANNEL, 2022–2027
FIGURE 15 GLOBAL MARKET, BY APPLICATION (2022–2027)
FIGURE 16 GLOBAL MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2022 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF DIGITAL THERAPEUTICS
4.2 GLOBAL MARKET, BY SALES CHANNEL, 2022–2027
FIGURE 19 B2B SALES DOMINATE GLOBAL MARKET
4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 NORTH AMERICA TO GROW AT HIGHEST RATE
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of preventable chronic diseases
5.2.1.2 Rising focus on preventive healthcare
5.2.1.3 Need to control healthcare costs
5.2.1.4 Significant increase in venture capital investments
5.2.1.5 Benefits of digital therapeutics
5.2.1.5.1 Ability to induce behavioral change
5.2.1.5.2 Improved drug adherence
5.2.1.5.3 Patient convenience and user-friendliness
5.2.2 RESTRAINTS
5.2.2.1 Patient data privacy concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Large undiagnosed and untreated population
5.2.3.3 Unexplored therapeutic applications
5.2.4 CHALLENGES
5.2.4.1 Unstable payment models
5.2.4.2 Reluctance among patients to adopt digital therapeutics
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries
5.2.4.4 Resistance from traditional healthcare providers
5.3 SUPPLY/VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
FIGURE 23 ECOSYSTEM ANALYSIS
5.5 PIPELINE PRODUCTS
5.6 CASE STUDIES
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 2 DIGITAL THERAPEUTICS REGULATORY FRAMEWORK
TABLE 3 GLOBAL MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES
5.9 TECHNOLOGY TRENDS
TABLE 4 TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES
5.10 INDUSTRY TRENDS
5.10.1 VIRTUAL REALITY
5.10.2 INCREASING DEMAND FOR DIGITAL DELIVERY OF BEHAVIORAL THERAPY
5.10.3 GROWING COLLABORATIONS BETWEEN STAKEHOLDERS
TABLE 5 DIGITAL THERAPEUTICS: RECENT COLLABORATIONS
5.11 PRICING ANALYSIS & REIMBURSEMENT SCENARIO
5.11.1 AVERAGE SELLING PRICE
TABLE 6 DIGITAL THERAPEUTICS PRODUCTS: REIMBURSEMENT & PRICE BY COUNTRY
5.11.2 REIMBURSEMENT SCENARIO
TABLE 7 DIGITAL THERAPEUTICS: GLOBAL COVERAGE DETERMINATION STANDARDS
5.12 PATENT ANALYSIS
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 8 GLOBAL MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL
TABLE 9 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL
5.14.2 BUYING CRITERIA
FIGURE 25 KEY BUYING CRITERIA FOR SALES CHANNEL
TABLE 10 KEY BUYING CRITERIA FOR SALES CHANNEL
6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (Page No. - 80)
6.1 INTRODUCTION
TABLE 11 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2 TREATMENT/CARE-RELATED APPLICATIONS
TABLE 12 GLOBAL MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 13 GLOBAL MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
6.2.1 DIABETES
6.2.1.1 Rising prevalence of diabetes to drive market growth
TABLE 14 GLOBAL MARKET FOR DIABETES, BY REGION, 2020–2027 (USD MILLION)
6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
TABLE 15 GLOBAL MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 16 GLOBAL MARKET FOR CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION)
6.2.2.1 Mental health disorders
6.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D
TABLE 17 GLOBAL MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2020–2027 (USD MILLION)
6.2.2.2 Other CNS disorders
TABLE 18 GLOBAL MARKET FOR OTHER CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION)
6.2.3 SMOKING CESSATION
6.2.3.1 Focus on providing validated, effective mobile applications to help quit smoking to aid market growth
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2020–2027 (USD MILLION)
6.2.4 CHRONIC RESPIRATORY DISEASES
6.2.4.1 Growing prevalence of COPD and asthma to drive market growth
TABLE 20 GLOBAL MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2020–2027 (USD MILLION)
6.2.5 MUSCULOSKELETAL DISORDERS
6.2.5.1 Dearth of physiotherapists to support market growth
TABLE 21 GLOBAL MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
6.2.6 CARDIOVASCULAR DISEASE
6.2.6.1 High burden of CVD to drive demand for digital therapeutics solutions
TABLE 22 GLOBAL MARKET FOR CVD, BY REGION, 2020–2027 (USD MILLION)
6.2.7 MEDICATION ADHERENCE
6.2.7.1 Growing number of medication non-adherence cases to propel market growth
TABLE 23 GLOBAL MARKET FOR MEDICATION ADHERENCE, BY REGION, 2020–2027 (USD MILLION)
6.2.8 GASTROINTESTINAL DISORDERS
6.2.8.1 High prevalence of gastrointestinal disorders to ensure strong interest in developing targeted solutions
TABLE 24 GLOBAL MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
6.2.9 REHABILITATION & PATIENT CARE
6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care
TABLE 25 GLOBAL MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2020–2027 (USD MILLION)
6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
6.2.10.1 Potential to improve efficiency of behavioral interventions to drive market growth
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2020–2027 (USD MILLION)
6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
TABLE 27 GLOBAL MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
6.3 PREVENTIVE APPLICATIONS
TABLE 28 GLOBAL MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 29 GLOBAL MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
6.3.1 PREDIABETES
6.3.1.1 Influx of startups to provide effective prevention against prediabetes to support market
TABLE 30 GLOBAL MARKET FOR PREDIABETES, BY REGION, 2020–2027 (USD MILLION)
6.3.2 OBESITY
6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth
TABLE 31 GLOBAL MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION)
6.3.3 NUTRITION
6.3.3.1 Importance of nutrition in preventing a wide range of ailments to drive demand for digital therapeutic solutions
TABLE 32 GLOBAL MARKET FOR NUTRITION, BY REGION, 2020–2027 (USD MILLION)
6.3.4 LIFESTYLE MANAGEMENT
6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes to contribute to rising demand
TABLE 33 GLOBAL MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2020–2027 (USD MILLION)
6.3.5 OTHER PREVENTIVE APPLICATIONS
TABLE 34 GLOBAL MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL (Page No. - 98)
7.1 INTRODUCTION
TABLE 35 GLOBAL MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
7.2 B2B
TABLE 36 GLOBAL MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 37 GLOBAL MARKET FOR B2B SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION)
7.2.1 PAYERS
7.2.1.1 Payers to hold largest share of B2B market
TABLE 38 GLOBAL MARKET FOR PAYERS, BY REGION, 2020–2027 (USD MILLION)
7.2.2 EMPLOYERS
7.2.2.1 Rising importance of employee health management to drive adoption of digital therapeutics among employers
TABLE 39 GLOBAL MARKET FOR EMPLOYERS, BY REGION, 2020–2027 (USD MILLION)
7.2.3 PHARMACEUTICAL COMPANIES
7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth
TABLE 40 GLOBAL MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
7.2.4 PROVIDERS
7.2.4.1 Potential for better patient management and cost-reduction to drive demand for digital therapeutics among providers
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2020–2027 (USD MILLION)
7.2.5 OTHER BUYERS
TABLE 42 GLOBAL MARKET FOR OTHER BUYERS, BY REGION, 2020–2027 (USD MILLION)
7.3 B2C
TABLE 43 GLOBAL MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 44 GLOBAL MARKET FOR B2C SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION)
7.3.1 CAREGIVERS
7.3.1.1 Ease of managing health conditions to drive demand for solutions among caregivers
TABLE 45 GLOBAL MARKET FOR CAREGIVERS, BY REGION, 2020–2027 (USD MILLION)
7.3.2 PATIENTS
7.3.2.1 Awareness of preventive health among patients to support segment growth
TABLE 46 GLOBAL MARKET FOR PATIENTS, BY REGION, 2020–2027 (USD MILLION)
8 DIGITAL THERAPEUTICS MARKET, BY REGION (Page No. - 107)
8.1 INTRODUCTION
TABLE 47 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT
TABLE 48 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Strong start-up base to ensure high product access for end users
TABLE 56 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 57 US: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 US: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 59 US: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 US: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 61 US: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 62 US: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada
TABLE 63 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 64 CANADA: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 65 CANADA: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 CANADA: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 CANADA: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 68 CANADA: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 69 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3 EUROPE
FIGURE 27 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT
TABLE 70 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 76 EUROPE: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Germany forms largest market for digital therapeutics in Europe due to supportive government initiatives
TABLE 78 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 79 GERMANY: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 GERMANY: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 GERMANY: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 GERMANY: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 83 GERMANY: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Well-established healthcare system and government support to propel market
TABLE 85 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 86 UK: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 UK: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 UK: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 UK: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 90 UK: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 91 UK: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market
TABLE 92 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 93 FRANCE: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 FRANCE: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 98 FRANCE: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.4 SPAIN
8.3.4.1 Initiatives by emerging digital therapeutics startups to drive market
TABLE 99 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 100 SPAIN: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 SPAIN: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 SPAIN: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 104 SPAIN: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 105 SPAIN: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Need for alternative and effective treatment to drive market
TABLE 106 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 ITALY: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 ITALY: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 ITALY: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 ITALY: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 111 ITALY: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 112 ITALY: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 113 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 114 ROE: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 ROE: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 ROE: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 ROE: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 118 ROE: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 119 ROE: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
TABLE 120 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 121 APAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 122 APAC: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 APAC: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 APAC: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 APAC: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 126 APAC: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 127 APAC: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Rising diabetes incidence and collaborations to drive market growth
TABLE 128 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 129 JAPAN: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 JAPAN: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 JAPAN: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 JAPAN: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 133 JAPAN: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 134 JAPAN: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing geriatric population and incidence of chronic conditions to drive demand
TABLE 135 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 136 CHINA: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 CHINA: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 CHINA: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 CHINA: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 140 CHINA: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 141 CHINA: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Rising chronic disease incidence and need for better disease management to drive market
TABLE 142 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 143 INDIA: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 INDIA: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 INDIA: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 INDIA: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 147 INDIA: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 148 INDIA: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 150 ROAPAC: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 ROAPAC: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 ROAPAC: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 ROAPAC: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 154 ROAPAC MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 155 ROAPAC: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 156 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 157 ROW: MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 ROW: MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 ROW: MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 ROW: MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION)
TABLE 161 ROW: MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
TABLE 162 ROW: MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 164)
9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL THERAPEUTICS
9.3 MARKET SHARE ANALYSIS
TABLE 163 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION
FIGURE 29 MARKET SHARE ANALYSIS: GLOBAL MARKET
9.4 MARKET RANKING ANALYSIS, 2022
FIGURE 30 GLOBAL MARKET RANKING ANALYSIS, 2022
9.5 COMPETITIVE BENCHMARKING
TABLE 164 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 165 GLOBAL MARKET: SALES CHANNEL FOOTPRINT OF KEY PLAYERS
TABLE 166 GLOBAL MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS
9.5.1 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY
TABLE 167 DIGITAL THERAPEUTICS MARKET: CRITERIA CONSIDERED FOR EVALUATION
9.5.1.1 Stars
9.5.1.2 Emerging leaders
9.5.1.3 Pervasive players
9.5.1.4 Participants
FIGURE 31 GLOBAL MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2022
9.5.2 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2022)
9.5.2.1 Progressive companies
9.5.2.2 Starting blocks
9.5.2.3 Responsive companies
9.5.2.4 Dynamic companies
FIGURE 32 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
9.6 COMPETITIVE SCENARIO
TABLE 168 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2019– AUGUST 2022
9.6.1 DEALS
TABLE 169 GLOBAL MARKET: DEALS, JANUARY 2019 - AUGUST 2022
9.6.2 OTHER DEVELOPMENTS
TABLE 170 GLOBAL MARKET: OTHER DEVELOPMENTS, JANUARY 2019 - AUGUST 2022
10 COMPANY PROFILES (Page No. - 177)
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOOM
TABLE 171 NOOM: BUSINESS OVERVIEW
10.1.2 TELADOC HEALTH
TABLE 172 TELADOC HEALTH: BUSINESS OVERVIEW
FIGURE 33 TELADOC HEALTH: COMPANY SNAPSHOT (2021)
10.1.3 OMADA HEALTH
TABLE 173 OMADA HEALTH: BUSINESS OVERVIEW
10.1.4 WELLDOC
TABLE 174 WELLDOC: BUSINESS OVERVIEW
10.1.5 PEAR THERAPEUTICS
TABLE 175 PEAR THERAPEUTICS: BUSINESS OVERVIEW
10.1.6 COGNIFIT
TABLE 176 COGNIFIT: BUSINESS OVERVIEW
10.1.7 GINGER
TABLE 177 GINGER: BUSINESS OVERVIEW
10.1.8 PROPELLER HEALTH
TABLE 178 PROPELLER HEALTH: BUSINESS OVERVIEW
10.1.9 2MORROW
TABLE 179 2MORROW: BUSINESS OVERVIEW
10.1.10 CANARY HEALTH
TABLE 180 CANARY HEALTH: BUSINESS OVERVIEW
10.1.11 CLICK THERAPEUTICS
TABLE 181 CLICK THERAPEUTICS: BUSINESS OVERVIEW
10.1.12 AKILI
TABLE 182 AKILI: BUSINESS OVERVIEW
10.1.13 WELLTHY THERAPEUTICS
TABLE 183 WELLTHY THERAPEUTICS: BUSINESS OVERVIEW
10.1.14 COGNOA
TABLE 184 COGNOA: BUSINESS OVERVIEW
10.1.15 TWILL
TABLE 185 TWILL: BUSINESS OVERVIEW
10.1.16 KAIA HEALTH
TABLE 186 KAIA HEALTH: BUSINESS OVERVIEW
10.1.17 BETTER THERAPEUTICS
TABLE 187 BETTER THERAPEUTICS: BUSINESS OVERVIEW
10.1.18 MINDSTRONG HEALTH
TABLE 188 MINDSTRONG HEALTH: BUSINESS OVERVIEW
10.1.19 BEHAVR
TABLE 189 BEHAVR: BUSINESS OVERVIEW
10.1.20 AYOGO
TABLE 190 AYOGO: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 MINDABLE HEALTH
10.2.2 VIRTA HEALTH CORP
10.2.3 HINGE HEALTH
10.2.4 OREXO AB
10.2.5 FREESPIRA
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 224)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
The study involved four major activities in estimating the current size of the global digital therapeutics market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the digital therapeutics market. Secondary sources include directories, databases such as Bloomberg Businessweek, Factiva, and the Wall Street Journal, white papers, and annual reports that were used to obtain key information about major players, market classification, and segmentation according to industry trends, regional and country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of primary respondents:
Note 1: C-level primaries include CEOs, CFOs, and COOs.
Note 2: Others include sales, marketing, and product and service managers.
Note 3: Tiers are defined based on a company’s total revenue, as of 2021: Tier 1 = >USD 100 million, Tier 2 = USD 100 million to USD 10 million, and Tier 3 =
To know about the assumptions considered for the study, download the pdf brochure
Digital Therapeutics Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the digital therapeutics market. These methods were also used extensively to determine the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The research methodology included the study of annual and quarterly financial reports and regulatory filings, data books of major market players, as well as interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global digital therapeutics market were determined by using secondary sources and verified through primary sources
- All key macro indicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data
- The gathered market data was consolidated and added with detailed inputs and analysis, and presented in this report
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the digital therapeutics market based on sales channel, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall digital therapeutics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)2
- To profile key players and analyze their market shares and core competencies3
- To track and analyze competitive developments such as product launches, partnerships, agreements, expansions, mergers, and acquisitions in the digital therapeutics market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report.
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Growth opportunities and latent adjacency in Digital Therapeutics Market
Which is the fastest growing market of Digital Therapeutics Market?
Which are the key factors driving the growth of the Global Digital Therapeutics Market?
What are the growth estimates for Digital Therapeutics Market till 2026?